PDCD1 and neoplasm: Although dual combination therapy with STING agonist and anti-PD-1 antibody prolonged overall survival, most mice experienced recurrence, wherein only a fraction of them (<10%) remained tumor-free and showed durable survival (figure 7A, B), indicating an incomplete survival benefit.